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BACKGROUND: CD44 and aldehyde dehydrogenase 1
(ALDH1) are considered putative markers of highly
tumorigenic cells (i.e., cancer stem-like cells) in head
and neck squamous cell carcinomas. This small subset
of cells is believed to be the primary responsible for
tumor initiation and progression. The objectives of this
study were (i) to evaluate the patterns of CD44 and
ALDH1 expression in the tumor center and in the
invasive front, as well as in adjacent non-tumor epithe-
lium, and (ii) to correlate these findings with clinical
parameters.
MATERIALS AND METHODS: The sample comprised
44 patients with primary head and neck squamous cell
carcinomas. Hematoxylin and eosin (HE) staining was
used for histopathological tumor grading and for mor-
phological analysis of adjacent non-tumor epithelium.
Semiquantitative analysis was performed in histological
sections immunostained for CD44 and ALDH1.
RESULTS: ALDH1 immunostaining in the invasive front
showed positive association with tumor size, regional
metastasis, tumor histopathological grading, and disease
progression. Moreover, expression of this marker in
both tumor invasive front and adjacent non-tumor
epithelium was related with more aggressive tumors.
CD44 immunostaining was heterogeneous in all areas
evaluated and did not show association with clinical
data.
CONCLUSION: Collectively, these data suggest that
ALDH1 immunostaining in the invasive front and in
adjacent non-tumor epithelium may help identify tumors
with a more aggressive behavior, potentially contributing
to improving treatment customization and the monitor-
ing of patients with head and neck cancer.
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Introduction
Emerging evidence suggests that a small subset of cells in
head and neck squamous cell carcinomas (HNSCCs) may be
primarily responsible for tumor initiation and progression.
This cell population has been shown to have an aggressive
biological behavior, with the ability to self-renew and to
generate heterogeneous lineages of cancer cells (1–15).
These cells have characteristics that are similar to those of
stem cells and have therefore been referred to as cancer
stem-like cells (14–19).
The identiﬁcation of highly tumorigenic cell populations
could contribute to the development of novel therapeutic
strategies and thus help mitigate the morbidity and mortality
associated with cancer (3). The combination of markers that
allow the identiﬁcation of these cells is known to be tumor
dependent. In HNSCCs, the markers most commonly used
to identify highly tumorigenic cells are CD44 and aldehyde
dehydrogenase 1 (ALDH1; 2, 8, 12, 14, 20, 21).
CD44 cells are a group of transmembrane glycoproteins
that act on cell–cell and cell–matrix interactions (9, 22, 23),
having hyaluronic acid (a widely abundant component of
the extracellular matrix) as the main ligand (10, 23). The
interaction between CD44 and hyaluronic acid activates
essential characteristics of tumor progression, e.g., cell
proliferation, survival, migration, and invasion (1, 10,
24–26). Some studies have reported a relationship between
CD44 immunostaining results and tumor behavior (9, 11,
24).
Aldehyde dehydrogenase 1, in turn, is a cytosolic enzyme
whose main function is to convert retinaldehyde into
retinoic acid in retinol metabolism (27). The by-products
of this metabolic process increase the self-renewal ability of
mesenchymal stem cells (27, 28). ALDH1 activity is found
in neoplastic cells, which show proliferative ability similar
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to that observed in stem cells and tumors with aggressive
clinical behavior (5, 9, 12, 17, 21, 27–31).
While many studies have demonstrated that ALDH+
CD44+ cells are highly tumorigenic, it remains unknown
whether the spatial distribution of these cells within human
tumors can be correlated with clinical outcomes. This
ﬁnding could be very useful in planning the postoperative
clinical management of patients with HNSCC.
Therefore, the primary objective of this study was to
assess the spatial distribution of CD44+ and ALDH1+ cells
in two different areas of HNSCCs (tumor center and
invasive front) and also in adjacent non-tumor epithelium in
specimens obtained from surgically treated patients. Possi-
ble associations between immunostaining data and clinical
parameters were also investigated.
Materials and methods
Patients
Our sample comprised 44 patients treated at the Head and
Neck Surgery Outpatient Clinic of Hospital de Clınicas de
Porto Alegre (HCPA). All patients presented with primary
HNSCC and had not undergone chemotherapy or radio-
therapy before surgery. Patient data, including gender, age,
ethnic origin, and exposure to risk factors, were collected in
an interview. Tumor location, size, regional and distant
metastasis (pTNM; 32), treatment protocol, and 3–4-year
follow-up data were also recorded. Outcome was classiﬁed
as failure (local, regional, or distant metastasis and death
due to tumor) and disease-speciﬁc survival. This study was
approved by the Research Ethics Committee of the institu-
tion of origin (protocol no. 09-315).
Immunohistochemistry
Parafﬁn blocks containing tumor center, invasive front, and
non-tumor epithelial specimens were selected for analysis.
Three 3-lm-thick sections were serially cut, of which two
were used for CD44 and ALDH1 immunostaining and one
for hematoxylin and eosin (HE) staining. Antigenic recov-
ery was performed using Dako retrieval solution, citrate
buffer pH 6.0 (Dako, Carpinteria, CA, USA), in water bath.
Anti-CD44 antibody (clone EPR1013Y, rabbit, Abcam,
Washington, DC, USA) was diluted at 1:100, and anti-
ALDH1 antibody (clone 44, mouse, BD Transduction
Laboratories, Franklin Lakes, NJ, USA) at 1:50. Non-
speciﬁc, isotype-matched IgG was used as a negative
control.
Histological analysis
Hematoxylin and eosin-stained slides were graded accord-
ing to the criteria set forth by Bryne et al. (33), into good,
moderate, and poor prognosis. Non-tumor epithelial tissue
located adjacent to HNSCC was classiﬁed according to
morphological characteristics into unaltered tissue, epithe-
lial hyperplasia, hyperkeratosis, acanthosis, and epithelial
dysplasia. Epithelial dysplasia was deﬁned as the presence
of structural and cytological abnormalities conﬁned to
epithelial layers, without invasion of other tissues. CD44
and ALDH1 immunostaining was assessed in the entire area
available, in both tumor and non-tumor epithelia. Cells
presenting brown staining in the membrane and cytoplasm/
nucleus were considered positive for CD44 (Fig. 1) and
ALDH1 (Fig. 2), respectively.
Immunohistochemical analysis was performed on both
the invasive front and tumor center. The invasive front was
deﬁned as the deepest cancer cell islands (Figs 3d and m).
Tumor center analysis focused on cancer cell islands located
in the central region of the lesion, discarding areas of
necrosis (Figs 3g and p). Adjacent non-tumor epithelium
was considered normal when CD44 expression was
observed in basal and parabasal layers, but not in superﬁcial
layers (Fig. 3L; 34).
Tumor markers CD44 and ALDH1 were semiquantita-
tively scored according to the proportion of cells stained in
the whole sample as follows: 0, negative; 1, <5% of positive
cells; 2, more than 5%; 3, 10–90%; and 4, more than 90% of
positive cells (35). As the statistical analysis did not show
differences in comparisons using four vs. two scores, CD44
and ALDH1 results were further classiﬁed into two groups,
namely positive (more than 5% of cells stained; Fig. 3B,C,
E,F,H,I) and negative (less than 5% of cells stained;
Fig. 3K,L,N,O,Q,R; 36).
Data analysis
All analyses were performed using the Statistical Package
for the Social Sciences (SPSS), version 18. Results were
tested for normality and revealed a normal distribution of
data. Associations between CD44/ALDH1 staining results
in the three regions assessed and clinical parameters were
assessed using Pearson’s chi-square test and Fisher’s exact
test (signiﬁcance level set at P < 0.05). Result reproduc-
ibility was conﬁrmed over the study period by selecting one
of every 20 slides (HE, CD44, and ALDH1) for reassess-
ment after a 7-day interval (j > 0.7). Examiners were blind
to the site of origin of each specimen.
Results
Mean patient age was 58 years (range: 37–78 years), and
there was a male predominance of 86.4%. Most patients
were currently or formerly exposed to tobacco and alcohol.
Detailed clinical data are summarized in Table 1. Of the 44
Figure 1 CD44-positive immunostaining in tumor cells. 4009 magniﬁ-
cation.
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tumors assessed, 65.9% were 4 cm in diameter or smaller
(T1 and T2), and 68.2% did not present regional metastases
at the moment of assessment. None of the patients presented
distant metastases. Most tumors were located in the oral
cavity, most frequently affecting the tongue, lower lip, and
ﬂoor of the mouth (Table 1).
Histopathological analysis revealed that 50% of the
tumors were considered to be of good prognosis, 38.6%
moderate, and 11.4% of poor prognosis. Most of the
adjacent epithelium samples were classiﬁed as epithelial
hyperplasia and hyperkeratosis (31.8% each), followed by
epithelial dysplasia (18.2%). Normal epithelium was found
in 13.6% of the samples (Table 1). Over the 3–4-year
follow-up period, 68.2% of the patients were free from
disease, whereas 25% showed disease recurrence/metastasis
or died (Table 1).
An association was found between ALDH1 immuno-
staining results in tumor areas and in adjacent non-tumor
epithelium, suggesting that ALDH1-positive tumors also
tend to show ALDH1-positive non-tumor epithelium
(Table 2). This association was not observed for CD44.
Table 3 shows CD44 and ALDH1 immunostaining
results in tumor and non-tumor epithelium in association
with clinical parameters and follow-up data. In the invasive
front, associations were observed between ALDH1 immu-
nostaining and tumor size (T3 and T4), presence of regional
metastases (N1, N2, N3), and histopathological grading
(good/moderate). Conversely, ALDH1 immunostaining in
the tumor center did not show any association with the
parameters assessed. In adjacent non-tumor epithelium
areas, an association was observed between ALDH1
immunostaining and histopathological grading and follow-
up data: 93.8% of the patients free from disease over the 3–
4-year follow-up period showed ALDH1-negative cells in
adjacent non-tumor epithelium (P = 0.019). These associ-
ations were not observed for CD44.
Discussion
Highly tumorigenic cancer stem-like cells present in
HNSCC have been considered responsible for the aggressive
biological behavior of this tumor (1–14 , 20, 21). Most
studies available in the literature describe the use of cell
culture techniques, ﬂow cytometry, or transplantation assays
in animal models to detect highly tumorigenic cells and thus
assess the pathobiology of HNSCC (1, 2, 5, 6, 37). Our
sample, in turn, was comprised of surgically removed
human primary HNSCC specimens, and highly tumorigenic
cells were identiﬁed in three different areas of the specimens
using the immunostaining method. Sample characteristics,
including mean age, gender, and exposure to risk factors
(tobacco and alcohol use), were in line with the typical
proﬁle described for patients diagnosed with HNSCC (30,
38, 39).
Head and neck squamous cell carcinomas cells are
heterogeneous within the same lesion, i.e., their cell
hierarchy allows us to ﬁnd subpopulations with exclusive
biological behaviors, e.g., tumor growth and metastatic
potential (1, 3, 19, 33). Our results showed positive CD44
and ALDH1 expression in both basal and suprabasal cells,
which may indicate that the immunohistochemical tech-
nique here employed was not appropriate to identify cancer
stem cells in HNSCCs based on these markers, as also
reported by other authors (31, 34). Moreover, no speciﬁc
markers have been established for the identiﬁcation of
cancer stem cell subpopulations in HNSCCs, as is the case
with other tumors (37). Notwithstanding, immunohisto-
chemistry did allow us to identify the location of positive
cells in different tumoral areas (tumor center and invasive
front), as well as in the different layers of adjacent non-
tumor epithelium. Also, our analysis revealed a positive
correlation between the spatial localization of ALDH1-
positive cells and clinical outcomes, especially in the
identiﬁcation of tumors with a more aggressive behavior,
despite the method’s failure identifying cancer stem cells.
Immunostaining results obtained for the two tumor areas
and non-tumor epithelium showed that tumors with
ALDH1-positive cells also presented positive surrounding
epithelial tissues. The concept of ﬁeld cancerization,
according to which carcinogen-induced changes would be
present in HNSCC-related non-tumor tissues before mor-
phological alterations can be found, was ﬁrst proposed by
Slaughter et al. (40) and later examined by Califano et al.
(41). We believe that our ﬁnding of ALDH1-positive cells
in adjacent non-tumor epithelium suggests that changes
were already underway, as this enzyme tends to be present
in cells with a high tumorigenic potential (12, 27, 29).
Conversely, immunostaining results for CD44 in the two
tumor areas and in adjacent non-tumor epithelium did not
reveal any signiﬁcant associations. No association was
found between CD44 expression and clinical parameters.
Notwithstanding, different results are reported in the
literature with the use of other CD44-positive cell detection
methods, e.g., ﬂow cytometry (2, 37). The value of CD44 as
a marker for highly tumorigenic cells has been questioned
previously (26), and some studies have suggested that it
may not be relevant in early diagnosis or as a prognostic
marker in HNSCCs (42, 43).
Indeed, previous studies have shown conﬂicting results
on the signiﬁcance of CD44 expression in head and neck
tumors (9, 24, 44–48). Studies employing immunochemistry
have shown that under-expression of CD44 standard form is
Figure 2 Aldehyde dehydrogenase 1-positive immunostaining in tumor
cells. 4009 magniﬁcation.
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Figure 3 Positive immunostaining in non-tumor epithelium (a: HE; b: ALDH1; c: CD44), tumor invasive front (d: HE; e: ALDH1; f: CD44), and tumor
center (g: HE; H: ALDH1; i: CD44). Negative immunostaining in non-tumor epithelium (j: HE; k: ALDH1; l: CD44), tumor invasive front (m: HE; n: ALDH1;
o: CD44), and tumor center (p: HE; q: ALDH1; r: CD44). 2009 magniﬁcation. ALDH1 = aldehyde dehydrogenase 1; HE = hematoxylin and eosin.
J Oral Pathol Med
Highly tumorigenic cells in HNSCC
Hildebrand et al.
502
a predictor of reduced survival (44, 45, 47). In contrast,
others have shown CD44 to be highly expressed in normal,
dysplastic, and tumoral head and neck epithelium (11, 24,
26). The expression of speciﬁc CD44 variants may be
reduced in tumors with a worse prognosis, but overall CD44
expression is not (46–48). Even though these varying results
may be due to the use of different antibodies and assessment
methods, CD44 immunostaining seems to be ineffective in
detecting highly tumorigenic cells in HNSCCs.
CD44 appears to be present at different stages of
carcinogenesis (24, 35). At ﬁrst, CD44 binding to hyal-
uronic acid in the extracellular matrix stabilizes neoplastic
cells in the invasive front, stimulating cell proliferation and
consequently the growth of cancer cell islands (24, 25).
Single-cell invasion shows a strongly positive expression of
CD44 around the entire plasma membrane (35). Subse-
quently, the loss of CD44 expression suggests a second
stage of tumor progression, in which cells lose their cell–cell
adhesion, facilitating mobility and consequently the inva-
sion and migration of neoplastic cells (22–25, 44).
Aldehyde dehydrogenase 1 staining in the tumor invasive
front and non-tumor tissues showed positive associations
with both clinical parameters (tumor size and presence of
regional metastasis) and histopathological grading results.
The lack of the same associations in the tumor center may
be due the biological behavior of neoplastic cells in this
region, i.e., less aggressive than cells of the invasive front
(33). The association of ALDH1 staining with lymph node
metastasis in HNSCC has been demonstrated previously
(30). ALDH1-positive tumor cells have high tumor-initiat-
ing ability and also high invasion ability, properties that
may be related to regional metastasis. In this sense, ALDH1
immunostaining may help identify tumor cells with an
undifferentiated phenotype, suggestive of tumors with a
stronger ability to invade surrounding tissues and develop
metastases (13, 21, 27–30).
In our sample, ALDH1 immunostaining results were
similar in tumor tissues and in non-tumor epithelium,
suggesting that this marker could be used as an instrument
to predict higher or lower risk of disease recurrence.
Moreover, an association was observed between ALDH1
immunostaining in non-tumor epithelium and follow-up
data: Of all adjacent epithelium specimens testing positive
for ALDH1, 35.7% showed metastases, local recurrence, or
death within 3–4 years, whereas 93.8% of disease-free
patients stained negative for ALDH1. This ﬁnding indicates
the presence of cells with a highly tumorigenic potential
even in cancer-free zones.
Table 1 Patient characteristics and tumor features
Clinical parameters n %
Age
Mean 58 –
Range 37–78 –
Gender
Male 38 86.4
Female 6 13.6
Tobacco
Current 19 43.2
Former 24 54.5
Never 1 2.3
Alcohol
Current 22 50
Former 20 45.5
Never 2 4.5
Follow-up (3–4 years)
Disease free 30 68.2
Metastasis/recurrence/
death
11 25
No data available 3 6.8
Histopathological grading
Good 22 50
Moderate 17 38.6
Poor 5 11.4
Size
T1 and T2 29 65.9
T3 and T4 15 34.1
Regional metastases
N0 30 68.2
N1, N2, and N3 14 31.8
Localization
Tongue 9 20.5
Lower lip 7 15.9
Floor of the mouth 6 13.6
Palate 4 9.1
Buccal mucosa 3 6.8
Neck 15 34.1
Non-tumor epithelium
Normal oral
epithelium
6 13.6
Epithelial hyperplasia 14 31.8
Hyperkeratosis 14 31.8
Acanthosis 2 4.6
Epithelial dysplasia 8 18.2
Total 44 100
Table 2 Association between (aldehyde dehydrogenase 1) ALDH1 and CD44 expression in tumor center, invasive front, and non-tumor epithelium
ALDH1
Non-tumor epithelium
CD44
Non-tumor epithelium
Positive Negative
P
Positive Negative
Pn % n % n % n %
Tumor Tumor
Invasive front Invasive front
Positive 19 67.9 3 18.8 0.005 Positive 19 54.3 4 44.4 0.716
Negative 9 32.1 13 81.3 Negative 16 45.7 5 55.6
Tumor Center Tumor Center
Positive 18 64.3 3 18.8 0.009 Positive 20 57.1 5 55.6 0.999
Negative 10 35.7 13 81.3 Negative 15 42.9 4 44.4
Total 44/100% 44/100%
Pearson’s chi-square test and Fisher’s exact test, P < 0.05.
Bold values are statistically signiﬁcance of P value.
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In conclusion, CD44 and ALDH1 expression did not
show a distinct spatial distribution pattern when invasive
front and tumor center specimens were compared. Further-
more, while CD44 expression did not show a clear
correlation with clinical outcomes, ALDH1 staining corre-
lated well with tumor size, presence of regional metastasis,
and histopathological grading. These results demonstrate
that ALDH1 is predominantly found in more aggressive
tumors, in both tumor areas and adjacent non-tumor
epithelium, and may therefore be useful in improving
treatment customization and the postoperative clinical
management of patients with head and neck cancer.
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